OneAscent Wealth Management LLC Acquires New Holdings in Eli Lilly and Company (NYSE:LLY)

OneAscent Wealth Management LLC purchased a new position in Eli Lilly and Company (NYSE:LLY) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 452 shares of the company’s stock, valued at approximately $400,000.

Several other institutional investors have also added to or reduced their stakes in the business. Meeder Advisory Services Inc. boosted its holdings in Eli Lilly and Company by 2.9% in the third quarter. Meeder Advisory Services Inc. now owns 15,761 shares of the company’s stock worth $13,963,000 after acquiring an additional 438 shares in the last quarter. Semus Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 27.2% in the third quarter. Semus Wealth Partners LLC now owns 3,101 shares of the company’s stock worth $2,747,000 after acquiring an additional 664 shares in the last quarter. MidAtlantic Capital Management Inc. acquired a new stake in Eli Lilly and Company in the third quarter worth about $30,000. Napa Wealth Management boosted its holdings in Eli Lilly and Company by 379.2% in the third quarter. Napa Wealth Management now owns 3,048 shares of the company’s stock worth $2,700,000 after acquiring an additional 2,412 shares in the last quarter. Finally, Cassaday & Co Wealth Management LLC boosted its holdings in Eli Lilly and Company by 2.1% in the third quarter. Cassaday & Co Wealth Management LLC now owns 5,570 shares of the company’s stock worth $4,935,000 after acquiring an additional 113 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY stock traded down $31.31 during trading on Monday, hitting $714.89. 1,229,976 shares of the company traded hands, compared to its average volume of 3,129,583. The stock’s 50-day simple moving average is $882.65 and its 200 day simple moving average is $871.04. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The company has a market cap of $678.66 billion, a PE ratio of 80.67, a P/E/G ratio of 2.82 and a beta of 0.43. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm’s quarterly revenue was up 20.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 earnings per share. On average, equities analysts expect that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on LLY shares. Berenberg Bank raised their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective for the company. BMO Capital Markets raised their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Barclays reduced their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Finally, Citigroup raised their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,007.94.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.